



Discovery of Novel or Alternative Interventions for Cancer Immunotherapy

Guest Editor:

Dr. Alexander Wu

The PhD Program for
Translational Medicine, College
of Medical Science and
Technology, Taipei Medical
University, Taipei 110, Taiwan

Deadline for manuscript
submissions:

closed (30 September 2022)

Message from the Guest Editor

Cancer immunotherapy has become a new modality of cancer treatment over the past decade. However, the majority of patients receiving immune checkpoint inhibitors still develop resistance eventually. Therefore, combinatory treatment regimens are vigorously tested in both preclinical and clinical settings. There is an urgent need to find novel small-molecule drugs with immunomodulating and anti-oncogenic properties.

We hope to obtain some studies on cancer immunotherapeutics based on novel small molecules (synthesized or inspired by natural compounds). Cutting-edge research should include:

- New classes of small-molecule drugs with immunotherapeutic potential;
- New cancer-immune biomarkers;
- New AI-assisted drug and cancer-immune biomarker discovery.

We are soliciting original articles and reviews involving new small-molecule compounds for cancer immunotherapy.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI